OncoMatch/Clinical Trials/NCT06019130
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
Is NCT06019130 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for nasopharyngeal carcinoma.
Treatment: Nivolumab · Cisplatin · 5-Fluorouracil · Gemcitabine · Interferon beta-1a — The purpose of this study is to assess whether the addition of the immune checkpoint inhibitor Nivolumab to induction chemotherapy will increase the percentage of patients with a complete response on MRI and PET after 3 cycles of induction therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: EBV positive
histologically confirmed new diagnosis of EBV-positive nasopharyngeal carcinoma
Required: PD-L1 (CD274) testing required (testing required; no eligibility threshold specified)
Sufficient tumor tissue to be sent for central review, including PD-L1 staining
Disease stage
Required: Stage II, III, IV (AJCC, 8th edition)
Excluded: Stage I
Stage II or higher in patients ≤ 25 years, stage III and IV in patients > 25 years (AJCC, 8th edition)
Demographics
Prior therapy
Cannot have received: chemotherapy
Prior chemotherapy and/or radiotherapy
Cannot have received: radiation therapy
Prior chemotherapy and/or radiotherapy
Cannot have received: anti-PD-1 therapy
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Cannot have received: anti-PD-L1 therapy
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Cannot have received: anti-PD-L2 therapy
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Cannot have received: anti-CTLA-4 therapy
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Cannot have received: checkpoint inhibitor
any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Lab requirements
Blood counts
WBC < 2 000/µl; Neutrophils < 1 500/µl; Platelets < 100 x 10e3/µL; Hemoglobin < 9.0 g/dL
Kidney function
Creatinine >1.5 x ULN or creatinine clearance < 50 mL/min (using Cockcroft Gault or Schwartz formula in patients < 18 years)
Liver function
AST/ALT > 3 x ULN (> 5 x ULN if liver metastases); Total Bilirubin > 1.5 x ULN (except Gilbert Syndrome ≥ 3.0 x ULN)
Inadequate hematologic, renal or hepatic function defined by any of the following screening laboratory values
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06019130 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EBV?
Yes, EBV positive is a required biomarker for enrollment.
Does this trial require CD274?
Yes, CD274 testing required is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify